reports
Myriad Genetics to Release First Quarter 2024 Financial Results on May...
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Management will also participate in four upcoming investor healthcare conferences SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to P...
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor 80% of people diagnosed with anxiety, depression report losing years or decades of time SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety and/or depression, according to the latest Mental Health Monitor, a nationwide survey from , Inc. (NASDAQ:MYGN), a leader in genetic testing and precis...
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High P...
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a 1 demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using Myriad’s prenatal cell-free DNA (pcfDNA) screen, Prequel®, which incorporates fetal fraction amplification. Prior studies from other commercial pcfDNA lab...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patie...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the . “We are encouraged by the initial results of this study that sh...
Myriad Genetics Announces Foundational Patent Granted for Molecular Re...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA...
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination. U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040. The patent further covers technology for improv...
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Finan...
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume.Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), and Hereditary Cancer (7%).Fourth quarter GAAP operati...
Myriad Genetics and National Cancer Center Hospital East in Japan Coll...
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-S...
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial...
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Management will also participate in two upcoming healthcare conferences SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company...
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Me...
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equ...
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid...
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the from Intermountain Health of select assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Myriad’s Test, which was also offered by IPG as TheraMap®: Solid Tumor, analyzes a...
Myriad Genetics Names George Daneker Jr., MD, as President and Chief C...
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laborator...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on Febru...
Myriad Genetics Applauds New Germline Testing Guideline for Patients w...
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer. The new offers multi-pronged, evidence-based clinical practice recommendations. Among the guidance includes: All patients with a current or previous diagnosis of invasive breast c...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Confe...
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST. The presentation will be available through a live webcast in the investor relations section of Myriad’s website at . An archived edition of the presentation will be available later that day. About Myriad Genetics Myriad G...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott ...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition. Riggsbee joined Myriad in 2014 as CFO. Dur...
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform...
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care The Myriad Collaborative Research Registry has more than one million patient cases SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the ™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest enhancements make the MCRR one of the largest pan-cancer ...
- Dave Nicoski
- Ross LaDuke
RGLD ROYAL GOLD INC
DPZ DOMINO'S PIZZA INC.
TRIP TRIPADVISOR INC.
PODD INSULET CORPORATION
PENN PENN NATIONAL GAMING INC.
OMI OWENS & MINOR INC.
NG. NOVAGOLD RESOURCES INC.
MYGN MYRIAD GENETICS INC.
MNRO MONRO INC
M MACY'S INC
KHC KRAFT HEINZ COMPANY
GCO GENESCO INC.
EMN EASTMAN CHEMICAL COMPANY
EDIT EDITAS MEDICINE INC.
ANIK ANIKA THERAPEUTICS INC.
UFCS UNITED FIRE GROUP INC.
AXP 11 88 0 SOLUTIONS AG
UA AMERICAN EXPRESS COMPANY
TGT UNDER ARMOUR INC. CLASS C
ALCO TARGET CORPORATION
VMD ALICO INC.
PNTG VIEMED HEALTHCARE
TWST PENNANT GROUP
ALXO TWIST BIOSCIENCE
CG ALX ONCOLOGY HOLDINGS
CLSK CARLYLE GROUP INC
BEAM CLEANSPARK
XMTR BEAM THERAPEUTICS
VSCO XOMETRY INC
EMBC VICTORIA'S SECRET & CO
VH EMBECTA CORP
VASTRA HAMNEN CORPORATE FINANCE AB
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with ...
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents SALT LAKE CITY, Nov. 20, 2023 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its . Since 2015, SneakPeek has been providing expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy. SneakPeek is 99% accurate1 and is one of the earliest ways to learn the baby’s predicted fetal sex. Customers can choose to take the test at home or...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma C...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests SALT LAKE CITY and FREMONT, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and , a leader in advanced genomics for precision oncology, (Nasdaq: PSNL) today announced a non-exclusive collaboration through which Myriad will market the Pers...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.